Revolutionizing HER2-Positive Breast Cancer Treatment: Insights from the 47th San Antonio Breast Cancer Symposium on Trastuzumab Deruxtecan

This editorial discusses the groundbreaking advancements in the treatment of HER2-positive breast cancer presented at the 47th San Antonio Breast Cancer Symposium, focusing on trastuzumab deruxtecan (T-DXd). T-DXd, an innovative antibody-drug conjugate, has shown significant improvements in progression-free survival (PFS) and overall survival (OS) compared to traditional chemotherapy, particularly in patients with HER2-positive metastatic breast cancer. Key studies, including DESTINY-Breast03 and DESTINY-Breast04, demonstrate T-DXd's efficacy and safety across diverse populations, including those with HER2-low tumors and brain metastases. The editorial also highlights the importance of real-world applications, ongoing research into biomarkers, and the potential of combination therapies, such as T-DXd with pyrotinib. The findings suggest that T-DXd not only extends survival but also enhances health-related quality of life for patients, promising a transformative shift in treatment paradigms for HER2-positive breast cancer.